Preferred Label : tocilizumab;

UMLS semantic type : T116 - Amino Acid, Peptide, or Protein; T129 - Immunologic Factor;

Is substance : O;

Details


Main resources

You can consult :


https://www.cochrane.org/fr/CD013484/EYES_quels-sont-les-benefices-et-les-risques-du-tocilizumab-un-medicament-qui-reduit-linflammation-dans
2021
United Kingdom
review of literature
french abstract
tocilizumab
risk assessment
Diseases
risks and benefits
tocilizumab
disease, nos
Arteritis
drug, nos
Blood vessel
giant cell arteritis
pharmaceutical preparations
Cell
inflammation
Inflammation
inflammation, nos
blood vessels
disease
Inflammation
giant cell arteritis
celiac disease
tocilizumab

---
https://www.usherbrooke.ca/baladocritique/archives/episode-41-etude-recovery-volet-tocilizumab
2021
Canada
COVID-19
sound
tocilizumab
tocilizumab
data collection
tocilizumab
episode of

---
https://www.has-sante.fr/jcms/p_3295750/fr/roactemra-tocilizumab
2021
France
evaluation of the transparency committee
tocilizumab
resulting in
registries
outcome studies
tocilizumab
tocilizumab
Roactemra
Outcome Assessment, Health Care

---
Nous contacter.
04/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.